Interestingly, patients with an IDH1 mutation had worse prognosis, as previously described by Wattad and colleagues [32] in a large study on primary refractory AML including patients with FLT3-mutated and wild-type disease, while those with IDH2-mutated AML had better outcomes. The gene discussed is IDH1; the disease is acute myeloid leukemia.